MedTrace Logo

Zepatier in Patients with Substance Use

NCT04048850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-01-28

No results posted yet for this study

Summary

The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use in urban, multidisciplinary specialty clinics.

Conditions

Interventions

DRUG

Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]

Daily medication

Sponsors & Collaborators

Principal Investigators

  • Rodrigo Mauricio Burgos, PharmD · University of Illinois at Chicago College of Pharmacy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2022-06-01
Completion
2022-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04048850 on ClinicalTrials.gov